ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2728-2737

  Donawho, Cherrie K ^a   Luo, Yan ^a   Luo, Yanping ^a   Penning, Thomas D ^a   Bauch, Joy L ^a   Bouska, Jennifer J ^a   Bontcheva Diaz, Velitchka D ^a   Cox, Bryan F ^a   DeWeese, Theodore L ^b   Dillehay, Larry E ^b   Ferguson, Debra C ^a   Ghoreishi Haack, Nayereh S ^a   Grimm, David R ^a   Guan, Ran ^a   Han, Edward K ^a   Holley Shanks, Rhonda R ^a   Hristov, Boris ^b   Idler, Kenneth B ^a   Jarvis, Ken ^a   Johnson, Eric F ^a   Kleinberg, Lawrence R ^b   Klinghofer, Vered ^a   Lasko, Loren M ^a   Liu, Xuesong ^a   Marsh, Kennan C ^a   McGonigal, Thomas P ^a   Meulbroek, Jonathan A ^a   Olson, Amanda M ^a   Palma, Joann P ^a   Rodriguez, Luis E ^a   Shi, Yan ^a   Stavropoulos, Jason A ^a   Tsurutani, Alan C ^a   Zhu, Gui Dong ^a   Rosenberg, Saul H ^a   Giranda, Vincent L ^a   Frost, David J ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 888; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOGS; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HAPLORHINI; HUMANS; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, INBRED STRAINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34249006299     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-3039     Document Type: Article

References (51)

1. Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
2. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000;460:1-15.
3. Masutani M, Nozaki T, Nakamoto K, et al. The response of Parp knockout mice against DNA damaging agents. Mutat Res 2000;462:159-66.
4. Amé JC, Rolli V, Schreiber V, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999;274:17860-8.
5. Menissierde Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63.
6. Tulin A, Chinenov Y, Spradling A. Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases. Curr Top Dev Biol 2003;56:55-83.
7. Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991;37:223-7.
8. Shiobara M, Miyazaki M, Ito H, et al. Enhanced poly-adenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-44.
9. Hayaishi O, Ueda K. Poly(ADP-ribose) and ADP-ribosylation of proteins. Annu Rev Biochem 1977;46:95-116.
10. Fukushima M, Kuzuya K, Ota Klkai K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett 1981;14:227-36.
11. Schreiber V, Ame JC, Dolle P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002;277:23028-36.
12. Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res 2000;451:39-51.
13. Curtin NJ, Wang LZ, Yiakouvaki A, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004;10:881-9.
14. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7.
15. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
16. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9.
17. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
18. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, MDurkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-15.
19. Lindahl T, Wood RD. Quality control by DNA repair: frontiers in cell biology: quality control. Science 1999; 286:1897-905.
20. Masutani M, Nozaki T, Nishiyama E, et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol Cell Biochem 1999;193:149-52.
21. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7.
22. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
23. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434: 913-7.
24. Sheridan C. Genentech raises stakes on PARP inhibitors. Nat Biotechnol 2006;24:1179-80.
25. Plummer ER. Inhibition of polyADP-ribose polymerase in cancer. Curr Opin Pharmacol 2006;6:364-8.
26. Kinders RJ, Palma J, Liu X, et al. Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity. In: The First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment; 2006; Chicago, IL.
27. Zhu GD, Gong J, Gandhi V, Penning TD, Giranda VL. 1H-Benzimidazole-4- carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors. United States patent application 2006/0229289. 2006.
28. Marcotte PA, Richardson PL, Guo J, et al. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem 2004;332:90-9.
29. Yee KWL, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-24.
30. Honore P, Donnelly-Roberts D, Namovic MT, et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl) -2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 2006; 319:1376-85.
31. Houghton PJ, Stewart CF, Thompson J, et al. Extending principles learned in model systems to clinical trials design. Oncology 1998;12:84-93.
32. Lapidus RG, Tentori L, Graziani G, et al. Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolamide against intracranial melanoma in mice. J Clin Oncol 2005;23:3136.
33. Zhou YZ, Sun Q, Lin SQ, et al. Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people. Zhonghua Yi Xue Za Zhi 2004;84:294-8.
34. Wong FMP, Bally M, B.Klasa R. Low dose antisense oligonucleotides to bcl-2 with cyclophosphamide cures SCID/Rag-2 mice with a human B cell lymphoma. In: 90th Annual Meeting of the American Association for Cancer Research; 1999 April 10-14; Philadelphia, Pennsylvania, USA. American Association for Cancer Research. Proceedings of the American Association for Cancer Research Annual Meeting. 1999.
35. 1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
36. 2 arrest after DNA damage. Science 1998;282:1497-501.
37. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52: 25-33.
38. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005;7:1-20.
39. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
40. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
41. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development, and clinical trials. Cancer Treat Rev 1997;23:35-61.
42. Benjamin RC, Gill DM. Poly ADP ribose synthesis in vitro programmed by damaged DNA: a comparison of DNA molecules containing different types of strand breaks. J Biol Chem 1980;255:10502-8.
43. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999;20:199-203.
44. O'Dwyer PJ, Johnson SW, Hamilton TC. Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: DeVitaVT, Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. Philadelphia (PA): Lippincott-Raven Publishers; 1997. p. 418-32.
45. Teicher BA. Antitumor alkylating agents. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia (PA): Lippincott-Raven Publishers; 1997. p. 405-18.
46. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to polyADP-ribose polymerase inhibition. Cancer Res 2006;66:8109-15.
47. Caldecott KW, Chalmers A. An Achilles' heel for breast cancer? Nat Struct Mol Biol 2005;12: 387-8.
48. Xing D, Orsulic S. A mouse model for the molecular characterization of BRCA1-associated ovarian carcinoma. Cancer Res 2006;66:8949-53.
49. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
50. De Soto JA. Deng C-X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 2006;3:117-23.
51. De Soto JA, Wang X, Tominaga Y, et al.The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006;2:179-85.